Crescent Biopharma, Inc. Common Stock

CBIONASDAQ • USD
14.10 USD
↘ 0.05 (0.38%)🟢PRE MARKET (AS OF 05:09 AM EST)
🟢Market: OPEN

Shares of Crescent Biopharma, Inc. Common Stock (CBIO) are trading at $14.10. Technicals currently rate "Neutral" while our fundamental analysis reads "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. CBIO is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Nov 13, 2026.

Open?$14.35
High?$14.35
Low?$14.10
Prev. Close?$14.15
Volume?0
Avg. Volume?270.4K
Bid / Ask
Bid?$11.74 × 100
Ask?$16.99 × 100
Spread?$5.25
Midpoint?$14.36
Valuation & Ratios
Market Cap?591.3M
Shares Out?37.1M
Float?28.1M
Float %?75.7%
P/E Ratio?N/A
P/B Ratio?2.16
EPS?-$3.83
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Employees
44
Market Cap
591.3M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2025-06-16
Address
300 FIFTH AVENUE
WALTHAM, MA 02451
Phone: 617-430-5595
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
33
Piotroski F-Score?0/9Weak
Altman Z-Score?11.99Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?14.81%High
Short Interest?4.2M
Days to Cover?16.3
Free Float28.1M
Avg Daily Volume255.5K
Settlement Date2026-10-30
Financial Health
Current Ratio?12.57Strong
Quick Ratio?12.57Strong
Cash Ratio?12.32Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
71
2.16CHEAP▾
P/S?
Peers
100
S&P
3
39.42HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.7CHEAP▾
EV/Sales?
Peers
100
S&P
3
20.13HIGH▾
Returns & Efficiency
ROE?
S&P
3
-58.4%WEAK▾
ROA?
S&P
3
-53.5%WEAK▾
Cash Flow & Enterprise
FCF?$-82430000
Enterprise Value?$301.9M
Fundamentals ratios updated end of day